Tarlatamab Receives New Indication for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Jun 01, 2026 14:46
CST Updated
17:14
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Developer of Molecular Targeted and Immune Anti-Tumor Drugs